Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 12/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.40 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.40 |
| ▸ | KIT | P10721 | 4/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049700 | 0.89 | PDGFRB (0.51) | MTNR1BPDGFRBPDGFRAMAPK7KIT | |
| SCHEMBL19032267 | 0.77 | MAPK7 (0.47) | MTNR1BPDGFRBMAPK7KITPDE3B | |
| SCHEMBL19032180 | 0.75 | PDE3B (0.42) | MTNR1BMAPK7KITPDE3BPDE3A | |
| SCHEMBL25275560 | 0.73 | PIM1 (0.48) | MAPK7KITPDE3BPDE3A | |
| SCHEMBL25423050 | 0.73 | MAPK7 (0.48) | MTNR1BPDGFRBMAPK7KITPDE3B | |
| SCHEMBL19032233 | 0.72 | MEN1 (0.46) | MAPK7KITPDE3BPDE3A | |
| SCHEMBL25232266 | 0.71 | MAPK7 (0.47) | MTNR1BMAPK7KIT | |
| SCHEMBL30405719 | 0.71 | MAPK7 (0.47) | MTNR1BMAPK7KIT | |
| SCHEMBL30406045 | 0.71 | MAPK7 (0.44) | MTNR1BMAPK7KIT | |
| SCHEMBL30543218 | 0.67 | AKT2 (0.46) | MTNR1BMAPK7KITPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-01-10 | — | — | US | disclosed |
| EP-3394064-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112768-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190010167-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | MTNR1B 1080/4885PDGFRB 3333/4885PDGFRA 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.